Your session is about to expire
← Back to Search
Ruxolitinib + Venetoclax for Acute Myeloid Leukemia
Study Summary
This trial is testing the combination of two drugs to treat acute myeloid leukemia that has returned or not responded to treatment. The first drug, ruxolitinib, may stop cancer cell growth by blocking enzymes needed for cell growth. The second drug, venetoclax, is a BCL-2 inhibitor that may stop cancer cell growth by blocking a protein needed for cancer cell survival. This study is being done to see if the combination of these two drugs works better than standard of care chemotherapy.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 149 Patients • NCT02038036Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Treatment (ruxolitinib, venetoclax)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the primary illnesses that Ruxolitinib has been utilized to address?
"Ruxolitinib is typically used as an intervention for steroid refractory. It can also be employed to manage a variety of other conditions, including graft-vs-host disease, chronic lymphocytic leukemia (CLL), and non-immunocompromised disorders."
What are the potential risks associated with taking Ruxolitinib?
"Our researchers at Power rated Ruxolitinib's safety a 1, as this is only Phase 1 and there is limited evidence of its efficacy and potential risks."
How many participants have enrolled in this study?
"At present, this research is not receiving new patients. The trial first appeared in records on August 16th 2019 and was edited as recently as 8/10/2022. There are plenty of other clinical trials that may be suitable for you; specifically, there are 1,604 studies recruiting people with leukemia or myeloid conditions and 314 which recruit those being treated with Ruxolitinib."
Are there any available slots to participate in this clinical research?
"Per the information on clinicaltrials.gov, this research endeavour is no longer recruiting participants and has not done so since August 10th 2022 when it was last updated. However, 1918 other trials are actively looking for patients at present time."
To what extent has Ruxolitinib been investigated in the past?
"Currently, there are 314 Ruxolitinib clinical trials being conducted worldwide. Of these studies, 40 have progressed to the Phase 3 stage of development. While Edmonton is home to a significant portion of those investigations, 10392 other locations around the world are also running similar experiments for this drug."
Share this study with friends
Copy Link
Messenger